# US 2004/0082066 A1 · Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082066 A1
- Document ID: US20040082066A1
- Status: Published application
- Kind: A1
- Application number: 10/609,670
- Filed: 2003-07-01
- Published: 2004-04-29
- Earliest claimed: 2002-07-01
- Assignees: Cytovia, Inc.
- Inventors: Sui Xiong Cai; Shailaja Kasibhatla; Kristin P. Ollis; Han-Zhong Zhang; John A. Drewe; Ben Tseng; Nilantha Sudath Sirisoma
- Web page: https://patentgrep.com/patent/US20040082066A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 493/20: Spiro-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention is directed to derivatives of gambogic acid and analogs thereof. Exemplary gambogic acid derivatives of the present invention include, among others, derivatives substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compounds of the present invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

## Claims

### Claim 1

A method of treating, preventing or ameliorating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, with reduced side effects at the site of administration and reduced systemic toxicity, comprising administering to a mammal in need of such treatment an effective amount of a compound having one of the Formulae I-II:
11
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
the dotted lines are single bonds, double bonds or an epoxy group;
X together with the attached carbon is a methylene, carbonyl, hydroxymethinyl, alkoxymethinyl, aminomethinyl, an oxime, a hydrazone, an arylhydrazone or semicarbazone;
Y together with the attached carbon is a methylene, carbonyl, hydroxymethinyl, alkoxymethinyl, aminomethinyl, an oxime, a hydrazone, an arylhydrazone or semicarbazone;
R1 is formyl, methylenehydroxy, carboxy, acyl (RaCO), optionally substituted alkoxycarbonyl (RaOCO), optionally substituted alkylthiocarbonyl, optionally substituted aminocarbonyl (carbamyl, RbRcNCO) or hydroxyaminocarbonyl, where Ra is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted lower aralkyl group; Rb and Rc are independently hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted lower aralkyl groups; or Rb and Rc may be taken together with the attached N to form a heterocycle, including piperidine, morpholine and piperazine;
R2 is hydrogen, optionally substituted alkyl, acyl (RaCO), carbamyl (RbRCNCO) or sulfonyl (RdSO2), where Ra, Rb and Rc are defined above; Rd is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted lower aralkyl groups;
R3 is hydrogen or prenyl;
R4 is hydrogen, halogen, hydroxy, alkoxy, arylalkoxy, aryloxy, heteroaryloxy, alkylthio, arylalkylthio, arylthio, heteroarylthio, amino, aminoalkoxy, optionally substituted saturated or partially saturated heterocylo, heterocycloalkoxy or heterocycloalkylamino; and
R5 is hydrogen, optionally substituted alkyl or acyl (RaCO), carbamyl (RbRcNCO) or sulfonyl (RdSO2), where Ra, Rb, Rc and Rd are defined above; wherein
said compound causes no side effects at the site of administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein Ra is —(CH2CH2O)nRm wherein n=1-10 and Rm is hydrogen or C1-10 alkyl.

### Claim 3 (depends on 2)

The method of claim 2, wherein R1 is 2-hydroxyethoxycarbonyl, 2-{2-[2-(2-methoxyethoxy)-ethoxy]ethoxy}ethoxy-carbonyl, 2-[2-(2-ethoxyethoxy)-ethoxy]ethoxycarbonyl, or 2-{2-[2-(2-octyloxyethoxy)ethoxy]ethoxy}ethoxy-carbonyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein R4 is 2-dimethylaminoethoxy, morpholinyl, 2-(morpholinyl)ethoxy, 2-(morpholinyl)ethylamino, piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl or 4-(2-pyridyl)piperazinyl.

### Claim 5 (depends on 1)

The method of claim 1, wherein said side effects are tissue damage or cell death at the site of administration.

### Claim 6 (depends on 5)

The method of claim 5, wherein said tissue is dermal, vascular, arterial, fatty or muscular tissue.

### Claim 7 (depends on 5)

The method of claim 5, wherein said tissue damage is necrosis, burning, irritation, eruption or inflammation.

### Claim 8 (depends on 1)

The method of claim 1, wherein said compounds have susbtantially reduced systemic toxicity.

### Claim 9 (depends on 1)

The method of claim 1, wherein said disorder is cancer.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said cancer is Hodgkin's disease, non-Hodgkin's lymphomas, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinomas, ovarian carcinomas, lung carcinomas, Wilms' tumor, cervical carcinomas, testicular carcinomas, soft-tissue sarcomas, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinomas, chronic granulocytic leukemia, primary brain carcinomas, malignant melanoma, small-cell lung carcinomas, stomach carcinomas, colon carcinomas, malignant pancreatic insulinoma, malignant carcinoid carcinomas, malignant melanomas, choriocarcinomas, mycosis fungoides, head and neck carcinomas, osteogenic sarcoma, pancreatic carcinomas, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinomas, thyroid carcinomas, esophageal carcinomas, malignant hypercalcemia, cervical hyperplasia, renal cell carcinomas, endometrial carcinomas, polycythemia vera, essential thrombocytosis, adrenal cortex carcinomas, skin cancer, or prostatic carcinomas.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said compound is administered together with at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

### Claim 12 (depends on 1)

The method of claim 1, wherein said disorder is drug resistant cancer.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said compound is administered together with at least one compound selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2′-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan®, arsenic trioxide, gamcitabine, doxazosin, terazosin, tamsulosin, CB-64D, CB-184, haloperidol, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, amprenavir, abacavir, CGP-73547, CGP-DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, BMS-232,632, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α-difluoromethylornithine, ILX23-7553, fenretinide, N-4-carboxyphenyl retinamide, lactacystin, MG-132, PS-341, Gleevec®, ZD1839 (Iressa), SH268, genistein, CEP2563, SU6668, SU11248, EMD121974, R115777, SCH66336, L-778,123, BAL9611, TAN-1813, flavopiridol, UCN-01, roscovitine, olomoucine, celecoxib, valecoxib, rofecoxib and alanosine.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said compound(s) are administered after surgical treatment for cancer.

### Claim 15 (depends on 9, 12)

The method according to claim 9 or 12, wherein said animal is also treated with radiation therapy.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said disorder is an autoimmune disease.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said disorder is an infectious viral disease.

### Claim 18 (depends on 1)

The method according to claim 1, wherein said disorder is rheumatoid arthritis.

### Claim 19 (depends on 1)

The method according to claim 1, wherein said disorder is an inflamatory disease.

### Claim 20 (depends on 1)

The method according to claim 1, wherein said disorder is psoriasis.

### Claim 21 (depends on 1)

The method according to claim 1, wherein said disorder is a skin disease.

### Claim 22 (depends on 1)

The method of claim 1, wherein said compound is selected from the group consisting of:
9,10-Dihydro-10-morpholinyl-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-piperidinyl-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethylamino]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethoxy]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-(2-dimethylaminoethoxy)-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-morpholinyl-gambogyl morpholine;
9,10-Dihydro-10-ethoxy-gambogyl piperidine;
9,10-Dihydro-10-morpholinyl-gambogyl (dimethylamine);
Ethyl 9,10-dihydro-10-morpholinyl-gambogate;
Methyl 9,10-dihydro-10-benzyloxy-gambogate;
Methyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate;
Methyl 9,10-dihydro-10-(piperidinyl)-gambogate;
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (diethylamine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (methylamine);
9,10-Dihydro-10-(morpholinyl)-gambogyl (diethylamine);
Methyl 9,10-dihydro-10-ethoxy-gambogate;
9,10-Dihydro-10-ethoxy-gambogic acid;
9,10-Dihydro-10-ethoxy-gambogyl (diethylamine);
Ethyl 9,10-dihydro-10-ethoxy-gambogate;
Methyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate;
Ethyl 9,10-dihydro-10-(piperidinyl)-gambogate;
Ethyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate; and
Ethyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate.

### Claim 23 (depends on 1)

The method of claim 1, wherein said compound is selected from the group consisting of:
9,10-Dihydro-10-morpholinyl-gambogyl piperidine;
9,10-Dihydro-10-(4-methylpiperazinyl)-gambogyl piperidine;
9,10-Dihydro-10-(4-methylpiperazinyl)-gambogyl morpholine;
9,10-Dihydro-10-piperidinyl-gambogyl piperidine;
9,10-Dihydro-10-(4-methylpiperazinyl)-gambogyl (4-methylpiperazine);
9,10-Dihydro-10-methoxy-gambogic acid;
9,10-Dihydro-10-butylthio-gambogic acid;
9,10-Dihydro-10-(4-methylpiperazinyl)-gambogic acid;
9,10-Dihydro-10-pyrrolidinyl-gambogic acid;
Methyl 9,10-dihydro-10-morpholinyl-gambogate;
9,10-Dihydro-10-piperidinyl-gambogic acid;
9,10-Dihydro-10-morpholinyl-gambogic acid;
9,10-Dihydro-10-(4-(2-pyridyl)piperazinyl)gambogyl (4-(2pyridyl)-piperazine);
9,10-Dihydro-10-(4-(2-pyridyl)piperazinyl)gambogic acid; and
9,10-Dihydro-10-methoxy-gambogyl piperidine.

### Claim 24 (depends on 1)

The method of claim 1, wherein said compound is selected from the group consisting of:
2-{2-[2-(2-Octyloxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl gambogate;
2-[2-(2-Ethoxyethoxy)ethoxy]ethyl 9,10-Dihydro-10-morpholinyl gambogate;
Propyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-Hydroxyethyl 9,10-Dihydro-10-morpholinyl-gambogate;
Methyl 9,10-Epoxy-gambogate;
Butyl 9,10-Dihydro-10-morpholinyl-gambogate;
Isobutyl 9,10-Dihydro-10-morpholinyl-gambogate;
Ethyl 3,4,9,10,32,33,37,38-Octahydro-10-morpholinyl-gambogate; and
Ethyl 3,4,9,10,27,28,32,33,37,38-Decahydro-10-morpholinyl-gambogate.

### Claim 25 (depends on 1)

The method of claim 1, wherein said compound is administered as part of an intravenous dosage form comprising an effective amount of said compound and a pharmaceutically acceptable formulation.

### Claim 26 (depends on 1)

The method of claim 1, wherein said effective amount is in the range of 0.01 mg/kg to 200 mg/kg.

### Claim 27

A method of treating, preventing or ameliorating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound selected from the group consisting of:
9,10-Dihydro-10-morpholinyl-gambogyl (N-methylpiperazine);
9,10-Dihydro-10-piperidinyl-gambogyl (N-methylpiperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethylamino]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethoxy]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-(2-dimethylaminoethoxy)-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-morpholinyl-gambogyl morpholine;
9,10-Dihydro-10-ethoxy-gambogyl piperidine;
9,10-Dihydro-10-morpholinyl-gambogyl (dimethylamine);
Ethyl 9,10-dihydro-10-morpholinyl-gambogate;
Methyl 9,10-dihydro-10-benzyloxy-gambogate;
Methyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate;
Methyl 9,10-dihydro-10-(piperidinyl)-gambogate;
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (diethylamine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (methylamine);
9,10-Dihydro-10-(morpholinyl)-gambogyl (diethylamine);
Methyl 9,10-dihydro-10-ethoxy-gambogate;
9,10-Dihydro-10-ethoxy-gambogic acid;
9,10-Dihydro-10-ethoxy-gambogyl (diethylamine);
Ethyl 9,10-dihydro-10-ethoxy-gambogate;
Methyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate;
Ethyl 9,10-dihydro-10-(piperidinyl)-gambogate;
Ethyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate;
Ethyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate;
Ethyl gambogate; and
Gambogyl methylamine.

### Claim 28 (depends on 27)

The method of claim 27, wherein said compound is selected from the group consisting of:
2-{2-[2-(2-Octyloxyethoxy)ethoxy]ethoxy}ethyl Gambogate;
2-{2-[2-(2-Octyloxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl gambogate;
2-[2-(2-Ethoxyethoxy)ethoxy]ethyl Gambogate;
2-[2-(2-Ethoxyethoxy)ethoxy]ethyl 9,10-Dihydro-10-morpholinyl gambogate;
Propyl gambogate;
Propyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}ethyl gambogate;
2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-Hydroxyethyl gambogate;
2-Hydroxyethyl 9,10-Dihydro-10-morpholinyl-gambogate;
Methyl 32,33-Epoxy-37,38-epoxy-gambogate;
Methyl 37,38-Epoxy gambogate;
Methyl 9,10-Epoxy-gambogate;
Butyl gambogate;
Isobutyl gambogate;
Butyl 9,10-Dihydro-10-morpholinyl-gambogate;
Isobutyl 9,10-Dihydro-10-morpholinyl-gambogate;
Ethyl 12-hydro-12-hydroxy-gambogate;
Ethyl 3,4,32,33,37,38-hexahydro-gambogate;
Ethyl 3,4,27,28,32,33,37,38-octahydro-gambogate
Ethyl 3,4,9,10,32,33,37,38-Octahydro-10-morpholinyl-gambogate; and
Ethyl 3,4,9,10,27,28,32,33,37,38-Decahydro-10-morpholinyl-gambogate.

### Claim 29 (depends on 28)

The method of claim 28, wherein said disorder is cancer.

### Claim 30 (depends on 29)

The method according to claim 29, wherein said cancer is Hodgkin's disease, non-Hodgkin's lymphomas, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinomas, ovarian carcinomas, lung carcinomas, Wilms' tumor, cervical carcinomas, testicular carcinomas, soft-tissue sarcomas, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinomas, chronic granulocytic leukemia, primary brain carcinomas, malignant melanoma, small-cell lung carcinomas, stomach carcinomas, colon carcinomas, malignant pancreatic insulinoma, malignant carcinoid carcinomas, malignant melanomas, choriocarcinomas, mycosis fungoides, head and neck carcinomas, osteogenic sarcoma, pancreatic carcinomas, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinomas, thyroid carcinomas, esophageal carcinomas, malignant hypercalcemia, cervical hyperplasia, renal cell carcinomas, endometrial carcinomas, polycythemia vera, essential thrombocytosis, adrenal cortex carcinomas, skin cancer, or prostatic carcinomas.

### Claim 31 (depends on 28)

The method of claim 28, wherein said disorder is drug resistant cancer.

### Claim 32 (depends on 29, 31)

The method according to claim 29 or 31, wherein said compound is administered together with at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said compound is administered together with at least one compound selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2′-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan®, arsenic trioxide, gamcitabine, doxazosin, terazosin, tamsulosin, CB-64D, CB-184, haloperidol, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, amprenavir, abacavir, CGP-73547, CGP-61755, DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, BMS-232,632, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α-difluoromethylornithine, ILX23-7553, fenretinide, N-4-carboxyphenyl retinamide, lactacystin, MG-132, PS-341, Gleevec®, ZD1839 (Iressa), SH268, genistein, CEP2563, SU6668, SU11248, EMD121974, R115777, SCH66336, L-778,123, BAL9611, TAN-1813, flavopiridol, UCN-01, roscovitine, olomoucine, celecoxib, valecoxib, rofecoxib and alanosine.

### Claim 34 (depends on 29, 31)

The method according to claim 29 or 31, wherein said animal is also treated with radiation therapy.

### Claim 35 (depends on 29, 31)

The method according to claim 29 or 31, wherein said compound(s) are administered after surgical treatment for cancer.

### Claim 36 (depends on 28)

The method according to claim 28, wherein said disorder is an autoimmune disease.

### Claim 37 (depends on 28)

The method according to claim 28, wherein said disorder is an infectious viral disease.

### Claim 38 (depends on 28)

The method according to claim 28, wherein said disorder is rheumatoid arthritis.

### Claim 39 (depends on 28)

The method according to claim 28, wherein said disorder is an inflamatory disease.

### Claim 40 (depends on 28)

The method according to claim 28, wherein said disorder is psoriasis.

### Claim 41 (depends on 28)

The method according to claim 28, wherein said disorder is a skin disease.

### Claim 42

A compound selected from the group consisting of:
9,10-Dihydro-10-morpholinyl-gambogyl (N-methylpiperazine);
9,10-Dihydro-10-piperidinyl-gambogyl (N-methylpiperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethylamino]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-[2-(morpholinyl)ethoxy]-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-(2-dimethylaminoethoxy)-gambogyl (N-methyl-piperazine);
9,10-Dihydro-10-morpholinyl-gambogyl morpholine;
9,10-Dihydro-10-ethoxy-gambogyl piperidine;
9,10-Dihydro-10-morpholinyl-gambogyl (dimethylamine);
Ethyl 9,10-dihydro-10-morpholinyl-gambogate;
Methyl 9,10-dihydro-10-benzyloxy-gambogate;
Methyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate;
Methyl 9,10-dihydro-10-(piperidinyl)-gambogate;
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (diethylamine);
9,10-Dihydro-10-[4-(2-pyridyl)piperazinyl]-gambogyl (methylamine);
9,10-Dihydro-10-(morpholinyl)-gambogyl (diethylamine);
Methyl 9,10-dihydro-10-ethoxy-gambogate;
9,10-Dihydro-10-ethoxy-gambogic acid;
9,10-Dihydro-10-ethoxy-gambogyl (diethylamine);
Ethyl 9,10-dihydro-10-ethoxy-gambogate;
Methyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate;
Ethyl 9,10-dihydro-10-(piperidinyl)-gambogate;
Ethyl 9,10-dihydro-10-(4-methylpiperazinyl)-gambogate;
Ethyl 9,10-dihydro-10-(4-acetylpiperazinyl)-gambogate;
Ethyl gambogate; and
Gambogyl methylamine.

### Claim 43

A compound selected from the group consisting of:
2-{2-[2-(2-Octyloxyethoxy)ethoxy]ethoxy}ethyl Gambogate;
2-{2-[2-(2-Octyloxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl gambogate;
2-[2-(2-Ethoxyethoxy)ethoxy]ethyl Gambogate;
2-[2-(2-Ethoxyethoxy)ethoxy]ethyl 9,10-Dihydro-10-morpholinyl gambogate;
Propyl Gambogate;
Propyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}ethyl gambogate;
2-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}ethyl 9,10-Dihydro-10-morpholinyl-gambogate;
2-Hydroxyethyl Gambogate;
2-Hydroxyethyl 9,10-Dihydro-10-morpholinyl-gambogate;
Methyl 9,10-Dihydro-gambogate and Methyl 9,10,12-Trihydro-12-hydroxy-gambogate;
Methyl 32,33-Epoxy-37,38-epoxy-gambogate and Methyl 37,38-Epoxy gambogate;
Methyl 9,10-Epoxy-gambogate;
Butyl Gambogate;
Isobutyl Gambogate;
Butyl 9,10-Dihydro-10-morpholinyl-gambogate;
Isobutyl 9,10-Dihydro-10-morpholinyl-gambogate;
3,4,9,10,32,33,37,38-Octahydro-gambogic Acid;
Ethyl 3,4,9,10,32,33,37,38-Octahydro-10-morpholinyl-gambogate;
Ethyl 3,4,32,33,37,38-Hexahydro-gambogate;
Ethyl 12-Hydro-12-hydroxy-gambogate;
Ethyl 9,10,12-Trihydro-12-hydroxy-gambogate;
Ethyl 3,4,9,10,27,28,32,33,37,38-Decahydro-10-morpholinyl-gambogate; and
Ethyl 3,4,27,28,32,33,37,38-Octahydro-gambogate.

### Claim 44 (depends on 42, 43)

A pharmaceutical composition, comprising a compound of claim 42 or 43 and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

### Claim 46 (depends on 44)

The pharmaceutical composition of claim 44, wherein said compound is administered together with at least one compound selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro2′-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan®, arsenic trioxide, gamcitabine, doxazosin, terazosin, tamsulosin, CB-64D, CB-184, haloperidol, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, amprenavir, abacavir, CGP-73547, CGP-61755, DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, BMS-232,632, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α-difluoromethylornithine, ILX23-7553, fenretinide, N-4-carboxyphenyl retinamide, lactacystin, MG-132, PS-341, Gleevec®, ZD1839 (Iressa), SH268, genistein, CEP2563, SU6668, SU11248, EMD121974, R115777, SCH66336, L-778,123, BAL9611, TAN-1813, flavopiridol, UCN-01, roscovitine, olomoucine, celecoxib, valecoxib, rofecoxib and alanosine.
